AR096885A1 - Partícula tipo virus que comprende antígeno pd-1 o antígeno de ligando pd-1 - Google Patents

Partícula tipo virus que comprende antígeno pd-1 o antígeno de ligando pd-1

Info

Publication number
AR096885A1
AR096885A1 ARP140102570A ARP140102570A AR096885A1 AR 096885 A1 AR096885 A1 AR 096885A1 AR P140102570 A ARP140102570 A AR P140102570A AR P140102570 A ARP140102570 A AR P140102570A AR 096885 A1 AR096885 A1 AR 096885A1
Authority
AR
Argentina
Prior art keywords
antigen
particle
type particle
ligand
seq
Prior art date
Application number
ARP140102570A
Other languages
English (en)
Inventor
Ueno Ryuji
Akahata Wataru
Original Assignee
Vlp Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlp Therapeutics Llc filed Critical Vlp Therapeutics Llc
Publication of AR096885A1 publication Critical patent/AR096885A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente proporciona una partícula de tipo viral que comprende una proteína estructural viral y un antígeno derivado de PD-1 o un ligando de PD-1 y una composición o kit que la comprende, su uso en la respuesta inmune, etc.. Reivindicación 4: La partícula de acuerdo con cualquiera de las reivindicaciones 1 - 3, caracterizada porque la partícula es partícula de tipo virus Chikungunya que consiste en una o varias proteínas de envoltura E2, en donde se inserta el antígeno derivado de PD-1, una o varias proteínas de envoltura El y una o varias cápsides y en donde la proteína de envoltura E2, en donde se inserta el antígeno derivado de PD-1 consiste en una secuencia de aminoácidos representada por SEQ ID Nº 33 - 35; la proteína de envoltura El consiste en una secuencia de aminoácidos representada por SEQ ID Nº 37; y la cápside consiste en una secuencia de aminoácidos representada por SEQ ID Nº 38. Reivindicación 14: Uso de la partícula de acuerdo con cualquiera de las reivindicaciones 1 - 8, la molécula de ácido nucleico de acuerdo con cualquiera de las reivindicaciones 9 - 11 y/o el vector de acuerdo con la reivindicación 11 caracterizado porque es para la producción de una composición farmacéutica o un kit para tratar o prevenir cáncer o una enfermedad infecciosa; producción de un anticuerpo contra PD-1 o un ligando de PD-1 en un mamífero; modulación de una respuesta inmune; inmunoestimulación; inhibición de una interacción entre PD-1 y un ligando de PD-1; o inhibición de una actividad de PD-1.
ARP140102570A 2013-07-12 2014-07-11 Partícula tipo virus que comprende antígeno pd-1 o antígeno de ligando pd-1 AR096885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361845712P 2013-07-12 2013-07-12

Publications (1)

Publication Number Publication Date
AR096885A1 true AR096885A1 (es) 2016-02-03

Family

ID=52277262

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102570A AR096885A1 (es) 2013-07-12 2014-07-11 Partícula tipo virus que comprende antígeno pd-1 o antígeno de ligando pd-1

Country Status (13)

Country Link
US (2) US9637532B2 (es)
EP (2) EP3666890A1 (es)
JP (1) JP6557208B2 (es)
KR (1) KR20160029124A (es)
CN (1) CN105358683A (es)
AR (1) AR096885A1 (es)
AU (1) AU2014288147B2 (es)
BR (1) BR112016000303A2 (es)
CA (1) CA2916458A1 (es)
IL (1) IL243304B (es)
MX (1) MX364952B (es)
TW (1) TWI676636B (es)
WO (1) WO2015005500A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404711WA (en) 2012-02-16 2014-09-26 Vlp Therapeutics Llc Virus like particle composition
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
KR20230097209A (ko) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
AU2015313650B2 (en) 2014-09-11 2021-07-08 Vlp Therapeutics, Inc. Flavivirus virus like particle
MX2017011732A (es) * 2015-03-18 2018-08-15 Omnicyte Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
US10166281B2 (en) * 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2018067361A1 (en) * 2016-10-04 2018-04-12 The Curators Of The University Of Missouri Peptides for molecular detection of pd-l1
SG11201908528UA (en) 2017-03-17 2019-10-30 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
BR112019020386A2 (pt) * 2017-03-28 2020-06-09 Mayo Found Medical Education & Res vacinas de peptídeos de pd-1 humana e usos das mesmas
AU2019216873A1 (en) * 2018-02-07 2020-08-20 Imugene Limited A vaccine composition and uses thereof
EP3762023A4 (en) * 2018-03-05 2021-12-29 New York University Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
JP7304421B2 (ja) * 2018-10-05 2023-07-06 アールエヌエージーン インコーポレイテッド 標的細胞特異的に結合して多重免疫機能が強化されたキメラ抗原及びこの用途
US20220064259A1 (en) * 2019-01-04 2022-03-03 George Mason Research Foundation, Inc. Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CN111116733B (zh) * 2019-11-28 2021-11-05 广东药科大学 一种靶向程序性死亡受体1和pd-1配体1相互作用界面的抗原肽和纳米抗体
JP2023514825A (ja) * 2020-02-26 2023-04-11 ヴェルシテック リミテッド コロナウイルス感染症に対するｐｄ－１ベースのワクチン
WO2024111633A1 (ja) * 2022-11-24 2024-05-30 国立大学法人徳島大学 タンパク質に対する抗体の作製

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
DE69228698T2 (de) 1991-11-16 1999-09-16 Smithkline Beecham Biologicals S.A., Rixensart HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
AU716466B2 (en) 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
EP1054973A1 (en) 1998-02-11 2000-11-29 Maxygen, Inc. Antigen library immunization
EP1210428B1 (en) * 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US20110262389A1 (en) 2001-02-13 2011-10-27 Mosca Joseph D Tumor-derived Biological Antigen Presenting Particles
JP4080423B2 (ja) 2001-05-30 2008-04-23 トランジェーヌ、ソシエテ、アノニム アデノウイルスタンパク質ｉｘ、ならびにキャプシドアセンブリー、転写活性および核再組織化に関与するそのドメイン
US7045335B2 (en) 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
WO2003102166A2 (en) 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20050031592A1 (en) 2002-11-13 2005-02-10 Doolan Denise L. Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines
WO2004055167A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
CA2527636A1 (en) 2003-05-29 2005-01-06 United States Army Medical Research Institute For Infectious Diseases, A Research Laboratory Owned And Operated By The United States Government A Live attenuated viral vaccines for eastern equine encephalitis virus
KR20060114340A (ko) 2003-12-01 2006-11-06 다우 글로벌 테크놀로지스 인크. 슈도모나드에서의 재조합 20면체 바이러스-유사 입자 생성
CA2567254C (en) * 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
KR20070104881A (ko) 2004-10-14 2007-10-29 크루셀 홀란드 비.브이. 말라리아 프라임/부스트 백신
JP4819792B2 (ja) 2005-02-16 2011-11-24 国立大学法人東京工業大学 改変されたウイルスカプシドタンパク質及びその使用
US8652465B2 (en) 2005-06-08 2014-02-18 Emory University Methods and compositions for the treatment of persistent infections
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP1997887B1 (en) 2006-03-03 2013-09-04 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
US7499304B2 (en) 2006-07-31 2009-03-03 Sandisk 3D Llc Systems for high bandwidth one time field-programmable memory
AU2007291936B2 (en) 2006-08-30 2012-09-27 Artes Biotechnology Gmbh Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
GB2453155A (en) 2007-09-26 2009-04-01 Rolls Royce Plc Co-axial pipe assembly which supplies oil to a bearing in a gas turbine engine
US20110035004A1 (en) 2007-11-14 2011-02-10 Maxwell G Interfaced medical implant
AU2008338803B2 (en) 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
EP2370455B1 (en) * 2008-11-26 2019-07-03 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
US20120219579A1 (en) 2009-09-18 2012-08-30 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
JP5600741B2 (ja) 2010-07-13 2014-10-01 帝人株式会社 炭素繊維束及びその製造方法、ならびにそれからの成形品
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
KR101792684B1 (ko) 2011-06-17 2017-11-02 브하라트 바이오테크 인터내셔날 리미티드 불활성화된 치쿤구니야 바이러스 균주를 포함하는 백신 조성물
WO2013009884A1 (en) 2011-07-12 2013-01-17 The Government Of The United States America As Represented By The Secretary Of The Department Of Health And Human Services Identification of a west nile virus cd4 t cell epitope and use thereof
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
WO2013056716A1 (en) * 2011-10-17 2013-04-25 Herlev Hospital Pd-l1 based immunotherapy
WO2013063248A1 (en) 2011-10-25 2013-05-02 Florida Gulf Coast University Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
SG11201404711WA (en) 2012-02-16 2014-09-26 Vlp Therapeutics Llc Virus like particle composition
CN108912215A (zh) 2012-04-02 2018-11-30 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
NZ701881A (en) * 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2014196648A1 (en) 2013-06-03 2014-12-11 Vlp Therapeutics, Llc Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
EP3119801B1 (en) 2014-03-18 2019-07-17 Fraunhofer Gesellschaft zur Förderung der Angewand Distinguishing flavivirus infection using a recombinant mutant envelope protein
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
AU2015313650B2 (en) 2014-09-11 2021-07-08 Vlp Therapeutics, Inc. Flavivirus virus like particle
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
WO2016199936A1 (ja) 2015-06-12 2016-12-15 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン
WO2016210127A1 (en) 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
EA035921B1 (ru) 2015-07-16 2020-08-31 Бхарат Байотек Интернэшнл Лимитед Вакцинные композиции для профилактики арбовирусных инфекций
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017150683A1 (en) 2016-03-04 2017-09-08 Vlp Therapeutics, Llc Zika virus virus like particle
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Also Published As

Publication number Publication date
JP6557208B2 (ja) 2019-08-07
IL243304B (en) 2020-02-27
US20150017194A1 (en) 2015-01-15
BR112016000303A2 (pt) 2017-12-12
IL243304A0 (en) 2016-03-31
CA2916458A1 (en) 2015-01-15
AU2014288147A1 (en) 2016-01-21
TWI676636B (zh) 2019-11-11
EP3666890A1 (en) 2020-06-17
TW201536812A (zh) 2015-10-01
EP3019600A1 (en) 2016-05-18
WO2015005500A1 (en) 2015-01-15
EP3019600A4 (en) 2017-04-12
CN105358683A (zh) 2016-02-24
US10464986B2 (en) 2019-11-05
MX364952B (es) 2019-05-14
KR20160029124A (ko) 2016-03-14
AU2014288147B2 (en) 2020-04-09
JP2016526374A (ja) 2016-09-05
MX2016000381A (es) 2016-09-07
EP3019600B1 (en) 2019-12-25
US20170233450A1 (en) 2017-08-17
US9637532B2 (en) 2017-05-02

Similar Documents

Publication Publication Date Title
AR096885A1 (es) Partícula tipo virus que comprende antígeno pd-1 o antígeno de ligando pd-1
CY1124437T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
MD4655B1 (ro) Virusurile bolii de Newcastle şi utilizarea acestora
CY1121934T1 (el) Αντισωματα anti-fcrn
AR127516A2 (es) VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN
CL2018001326A1 (es) Proteínas de unión a ctla4.
EA202090739A1 (ru) Белки, связывающие антиген созревания в-клеток
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
WO2017015463A3 (en) Infectious disease vaccines
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
CO2019014684A2 (es) Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
EA201792045A1 (ru) Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr
CO2018012513A2 (es) Anticuerpos
WO2014134561A3 (en) Quantification of vaccine compositions
CA2872308A1 (en) Novel ha binding agents
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
AR093357A1 (es) Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
PE20160528A1 (es) Anticuerpos
BR112019007309A2 (pt) anticorpos anti-c1s e métodos de uso dos mesmos
AU2018273963A1 (en) Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Legal Events

Date Code Title Description
FB Suspension of granting procedure